Results from a Phase 2 trial investigating Eloralintide for obesity or overweight were posted on 2026-06-24. The study demonstrated a significant dose-dependent reduction in body weight, with the highest dose achieving a least squares mean reduction of up to 20.1% from baseline at Week 48 compared to placebo.
Background
Eloralintide was investigated in this study for its potential in weight management for adult participants diagnosed with obesity or overweight.
Trial design
This was a Phase 2 trial (NCT06230523) that enrolled 263 adult participants. The study compared different doses of Eloralintide against placebo in individuals with obesity or overweight. The trial duration was approximately 64 weeks.
Key results
The trial reported key measurements for the percent change from baseline in body weight at Week 48:
- Participants receiving placebo showed a least squares mean percent change of -0.4% (Standard Error: 0.91).
- Participants receiving 1 mg Eloralintide showed a least squares mean percent change of -9.4% (Standard Error: 1.60).
- Participants receiving 3 mg Eloralintide showed a least squares mean percent change of -12.4% (Standard Error: 1.30).
- Participants receiving 6 mg Eloralintide showed a least squares mean percent change of -17.6% (Standard Error: 1.56).
- Participants receiving 9 mg Eloralintide showed a least squares mean percent change of -20.1% (Standard Error: 1.31).
- Participants receiving 6/9 mg Eloralintide showed a least squares mean percent change of -19.9% (Standard Error: 1.45).
- Participants receiving 3/6/9 mg Eloralintide showed a least squares mean percent change of -16.5% (Standard Error: 1.18).
For absolute change from baseline in body weight at Week 48 (in Kilograms):
- Participants receiving placebo showed a least squares mean change of -0.2 Kilograms (Kg) (Standard Error: 1.01).
- Participants receiving 1 mg Eloralintide showed a least squares mean change of -10.2 Kilograms (Kg) (Standard Error: 1.66).
- Participants receiving 3 mg Eloralintide showed a least squares mean change of -13.3 Kilograms (Kg) (Standard Error: 1.37).
- Participants receiving 6 mg Eloralintide showed a least squares mean change of -18.7 Kilograms (Kg) (Standard Error: 1.81).
- Participants receiving 9 mg Eloralintide showed a least squares mean change of -21.3 Kilograms (Kg) (Standard Error: 1.41).
What this means
The results from this Phase 2 study indicate that Eloralintide demonstrated a dose-dependent efficacy in reducing body weight in adults with obesity or overweight. The observed least squares mean percent weight reductions, reaching up to 20.1% at the 9 mg dose, suggest a clinically meaningful effect compared to placebo. These findings support the continued development of Eloralintide as a potential treatment option for weight management.
Source
The trial results were posted on 2026-06-24 on ClinicalTrials.gov, an official database of clinical studies. The full details are available on clinicaltrials.gov under the identifier NCT06230523.